HSBC loses conviction in leading drugmaker, forecasts 'tough path' ahead

The bank's analysts wrote in a note on Monday that they have downgraded the stock to 'hold', as the team "no longer finds the risk-reward balance attractive."

CryptoAlerta — análise de criptomoedas e mercado em tempo real